Statement from Critical Path Institute Board Chair Wainwright Fishburn on the Senate Confirmation of Dr. Robert M. Califf, MD, MACC, as Commissioner of the U.S. Food and Drug Administration (FDA), Feb. 15, 2022.
The Critical Path Institute (C-Path) congratulates Dr. Robert Califf on his Senate confirmation as Commissioner of the FDA. Dr. Califf has been a valued member of the C-Path Board and Wainwright Fishburn, C-Path Board Chair, observed, “For decades, Dr. Califf has been an influential voice stressing the importance of public-private partnerships to transform data for the accelerated development of new patient-centric medical products. Collaborations are at the foundation of C-Path’s work and we are confident Dr. Califf’s FDA contributions will be impactful. We look forward to continuing our work with Commissioner Califf, Principal Deputy Commissioner Dr. Janet Woodcock and their FDA colleagues. We applaud their commitment to public health and are confident their leadership will strengthen the FDA as we overcome the pandemic and address other unmet healthcare needs.”
Critical Path Institute (C-Path) is an independent, nonprofit organization established in 2005 as a public and private partnership. C-Path’s mission is to catalyze the development of new approaches that advance medical innovation and regulatory science, accelerating the path to a healthier world. An international leader in forming collaborations, C-Path has established numerous global consortia that currently include more than 1,600 scientists from government and regulatory agencies, academia, patient organizations, disease foundations, and dozens of pharmaceutical and biotech companies. C-Path U.S. is headquartered in Tucson, Arizona and C-Path, Ltd. EU is headquartered in Dublin, Ireland, with additional staff in multiple other locations. For more information, visit c-path.org and c-path.eu.